ABCG2 and hyperuricemia: With regard to the treatment of cardiovascular comorbidities in hyperuricemia patients, it should be noted that blood pressure-lowering drugs such as the AT1 receptor blocker telmisartan have been shown to inhibit the transport activity of ABCG2 [75] thereby potentially exacerbating hyperuricemia in patients with a corresponding genetic predisposition.